Elana Fertig named associate director for quantitative science at University of Maryland Greenebaum

Researchers identify HMGA1 as key driver in colon cancer development

A gene called high mobility group A1 may be the key that opens the door to the development of colon cancer, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, Johns Hopkins Department of Medicine, Johns Hopkins Department of Pathology and the Johns Hopkins Institute for Cell Engineering.

February 28, 2025

Vol.51 No.08

Clinical Roundup

Epigenetic research reveals a potential treatment for CRC and other solid tumors

A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells and potentially could be used to treat solid tumors, according to a new study from researchers at the Johns Hopkins Kimmel Cancer Center and the Chinese Academy of Sciences.

January 17, 2025

Vol.51 No.02

In Brief

Johns Hopkins, Howard University reform collaboration to advance health equity

A collaborative effort to eliminate cancer health disparities among African Americans and other underserved populations in the Washington, DC, area is being reignited at the Johns Hopkins Kimmel Cancer Center and the Howard University Cancer Center.

January 10, 2025

Vol.51 No.01

In Brief

Stephen Baylin and Andrew Feinberg, of Johns Hopkins, win Technion’s Harvey Prize

Stephen BaylinAndrew FeinbergJohns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center researchers Stephen Baylin and Andrew Feinberg were awarded the 2022–2023 Harvey Prize in the field of Science and Technology by the Technion—Israel Institute of Technology.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Scientists identify genes that help cancer cells survive in the bloodstream

Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they’ve escaped the low-oxygen regions of a tumor. Each is a potential therapeutic target to stop cancer recurrence, and one—MUC1—is already in clinical trials. The research was published online Sept. 28 in...

November 08, 2024

Vol.50 No.42

Clinical Roundup

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.

September 13, 2024

Vol.50 No.34

Elana Fertig named associate director for quantitative science at University of Maryland Greenebaum

YOU MAY BE INTERESTED IN

Researchers identify HMGA1 as key driver in colon cancer development

Epigenetic research reveals a potential treatment for CRC and other solid tumors

Johns Hopkins, Howard University reform collaboration to advance health equity

Stephen Baylin and Andrew Feinberg, of Johns Hopkins, win Technion’s Harvey Prize

Scientists identify genes that help cancer cells survive in the bloodstream

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

Renew today!

Subscriber content

Never miss an issue!

Login